Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- INZY
- Price
- 3.99
- Stock movement up
- +- (%)
- Company name
- Inozyme Pharma Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 258.25M
- Ent value
- 294.25M
- Price/Sales
- 130.69
- Price/Book
- 3.12
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -10.31%
- 3 year return
- -8.14%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-09-12
DIVIDENDS
INZY does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 130.69 |
| Price to Book | 3.12 |
| EV to Sales | 148.91 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 64.56M |
| EPS (TTM) | -1.52 |
| FCF per share (TTM) | -1.44 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.98M |
| Gross profit (TTM) | 1.10M |
| Operating income (TTM) | -99.67M |
| Net income (TTM) | -96.49M |
| EPS (TTM) | -1.52 |
| EPS (1y forward) | -1.08 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 55.92% |
| Operating margin (TTM) | -5043.98% |
| Profit margin (TTM) | -4883.30% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 24.57M |
| Net receivables | 0.00 |
| Total current assets | 140.94M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 143.36M |
| Accounts payable | 2.21M |
| Short/Current long term debt | 46.79M |
| Total current liabilities | 18.34M |
| Total liabilities | 60.57M |
| Shareholder's equity | 82.79M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -91.21M |
| Capital expenditures (TTM) | 150.00K |
| Free cash flow (TTM) | -91.36M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -116.56% |
| Return on Assets | -67.31% |
| Return on Invested Capital | -109.24% |
| Cash Return on Invested Capital | -103.42% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 4.00 |
| Daily high | 4.00 |
| Daily low | 4.00 |
| Daily Volume | 0K |
| All-time high | 30.20 |
| 1y analyst estimate | 4.00 |
| Beta | 2.29 |
| EPS (TTM) | -1.52 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| INZY | S&P500 | |
| Current price drop from All-time high | -86.75% | - |
| Highest price drop | -97.28% | -56.47% |
| Date of highest drop | 4 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -72.39% | -10.99% |
| Avg time to new high | 113 days | 12 days |
| Max time to new high | 1214 days | 1805 days |
COMPANY DETAILS
Marketcap
258.25M
Marketcap category
Small-cap
Description
Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney disease receiving hemodialysis. It also develops Next Gen ERT for the treatment of ossification of the posterior longitudinal ligament (OPLL); and Gene therapy, a disease of the PPi-Adenosine Pathway. The company has license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Employees
67
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner